reference 3
To Whom It May Concern:
Re: John Hare – Hare and Associates
I was the Production Manager at the Winnipeg production facility of Inovatech Egg Products (a division of MFI Food Canada Inc., and formerly Canadian Inovatech Inc.) until October 2011. Inovatech Winnipeg was the largest egg processing facility in Canada. Our facility began custom processing antibody enhanced eggs for Hare and Associates beginning the fall of 2000 and continued up to the time that I left the company.
Hare and Associates would inoculate hens, on contracted egg farms, with proprietary and specific vaccines. The eggs would be shipped to the IEP Winnipeg plant for custom processing. This process included receiving and segregating the eggs, breaking and collection of egg liquid, filtering, pasteurization, spray drying, packaging, and QA testing. Throughout this time, we processed in excess of 100,000 litres of liquid egg from more than 1 million eggs.
I attest to all of the above. If you require more information you can contact me by e mail John.Thoroski@umanitoba.ca or phone #204 474 9332.
Sincerely,
John Thoroski
Instructor and Dairy Plant Manager
University of Manitoba
reference 4
Manitoba Egg Farmers and its farmer members have successfully collaborated with J. H. Hare & Associates Ltd on past projects to produce biologics derived from antiody egg production targeted at livestock and human health challenges. MEF contributed real dollars to their Health Canada-approved Phase 2 human clinical trial testing a product to prevent and combat Clostridium difficile infections in humans.
Cory Rybuck
reference 5
We have been a customer of John Hare and his Hyper-Egg Antibody product for many years. It has been an effective way to protect animals against E. Coli bacteria Infection.
They have shown their ability to harvest specific Antibodies from eggs, and legitimized the technology with two Canadian Food Inspection Agency registered Veterinary Biologic treatments.
Their 23 years experience in this field should lend itself well to developing an Antibody against COVID-19. We support John and his company in using their egg Antibody-Vaccine therapy to bring an end to this and possible future pandemics.
Dr Maurice Verschaeve dvm
Emma Nutrition bv
8970 Poperinge
Belgium
20 years of collaboration AND COSTUMER with good results with the HONEST product.
www.emma.be
reference 6
J. H. Hare & Associates Ltd is a successful family owned private company registered in Manitoba, Canada. I have handled all accounting and tax filing for John and his father before him since 1970.
Over this time I have also gotten to know John well and have been aware of his business operations. Several of my other accounting clients and myself are invested with John in the same egg Antibody-Vaccine therapy to treat human C Difficile Infection. The treatment has demonstrated efficacy and safety and they are presently recruiting patients for a phase 2 clinical trial sanctioned by Health Canada.
We invested because we have confidence in both the treatment potential and John's ability to deliver.
Richard Gamble, CPA, CA
reference 7
My name is Menna Desta. I have worked with John Hare since 2007 as a lab technician, responsible for production of E. Coli vaccine. This vaccine starts the process for one of the company's registered Veterinary Biologic treatments, with the claim "to aid in the prevention of diarrhea caused by E. Coli bacteria."
The same egg Antibodies are used in IMMUNADE, a human Microbiome Therapy product. I personally take IMMUNADE everyday and have been able to stop using two asthma medications and my PPI, which I had been taking for over ten years. I haven't used any of these meds for over three years.
The technology works for animals and humans and we are hopeful it will work against Coronavirus.
Menna Desta
reference 8
I have known John Hare in a professional capacity for over 25 Years. I witnessed John’s team successfully compete for research funding and bring the novel antibody technology to market.
Having had the opportunity to learn of the technology in my professional career, I was an early adopter when Immunade came to market. I take Immunade daily and have a travel pack with me whenever I travel. I also successfully moved away from a proton pump inhibitor (Nexium) prescription and have been symptom free over 9 months by taking Immunade daily.
Finally, when the opportunity presented itself for me to invest in John’s team, and the extension of this novel technology to new markets —I jumped in immediately. This technology has the ability to be a game changer in gut health and disease management.
Dr. Tracy Gilson, PhD, MBA, PAg